Log In
BCIQ
Print this Print this
 

RK-023

  Manage Alerts
Collapse Summary General Information
Company Sucampo Pharmaceuticals Inc.
DescriptionUnoprostone isopropyl analog
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$273.9M

$273.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/07/2015

$273.9M

$273.9M

0

Get a free BioCentury trial today